Author:
Erdes Sh.,Mazurov V. I.,Gaydukova I. Z.,Anoshenkova O. N.,Vinogradova I. B.,Grabovetskaya Yu. Yu.,Davidian S. Y.,Kiryukhina N. A.,Epifanova O. E.,Masneva L. V.,Menshikova L. V.,Mironenko O. N.,Nikulenkova N. E.,Povarova T. V.,Poliatika A. N.,Samigullina R. R.,Sizikov A. E.,Totrov I. N.,Umnova I. F.,Usacheva J. V.,Chudinov A. L.
Reference16 articles.
1. Sieper, J., Braun, J., Dougados, M., and Baeten, D., Axial spondyloarthritis, Nat. Rev. Dis. Prim., 2015, vol. 1, p. 15013.
2. Merino, M., Braçe, O., González-Domínguez, A., et al., Social economic costs of ankylosing spondylitis in Spain, Clin. Exp. Rheumatol., 2021, vol. 39, no. 2, pp. 357–364.
3. Shukla, R. and Goodacre, J., The impact of ankylosing spondylitis/axial spondyloarthritis on work productivity, Best Pract. Res. Clin. Rheumatol., 2015, vol. 29, no. 3, pp. 512–523.
4. Ramiro, S., Nikiphorou, E., Sepriano, A., et al., ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update, Ann. Rheum. Dis., 2023, vol. 82, pp. 19–34.
5. Gaidukova, I.Z., Rebrov, A.P., and Lapshina, S.A., Use of nonsteroidal anti-inflammatory drugs and biological agents for the treatment of axial spondyloarthritides. Recommendations of the Spondyloarthritis Study Group of Experts, All-Russian Public Organization “The Association of Rheumatology of Russia,” Nauchno-Prakt.
Revmatol., 2017, vol. 55, no. 5, pp. 474–484.